Sustained release intraocular implants and methods for preventing retinal dysfunction
First Claim
Patent Images
1. A biodegradable intraocular implant comprising:
- an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the alpha-2 adrenergic receptor agonist from the implant effective to enhance normal retinal neuronal function in an eye in which the implant is placed.
2 Assignments
0 Petitions
Accused Products
Abstract
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.
-
Citations
38 Claims
-
1. A biodegradable intraocular implant comprising:
an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the alpha-2 adrenergic receptor agonist from the implant effective to enhance normal retinal neuronal function in an eye in which the implant is placed. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
21. A method of making a biodegradable intraocular implant, comprising the step of:
- extruding a mixture of an alpha-2 adrenergic receptor agonist and a biodegradable polymer component to form a biodegradable material that releases drug at a rate effective to sustain release of an amount of the alpha-2 adrenergic receptor agonist from the implant effective to enhance normal retinal neuronal function in an eye in which the implant is placed.
- View Dependent Claims (22, 23, 24, 25, 26, 27)
- 28. A method of treating a retinal dysfunction in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the alpha-2 adrenergic receptor agonist from the implant to provide an amount of the alpha-2 adrenergic receptor agonist effective to prevent or reduce a symptom of a retinal dysfunction.
Specification